Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sancailianmei Particles
- Development stage
- Unknown
- Lead developer
- Hospital of Chengdu University of Traditional Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sancailianmei Particles (also known as Sancai Lianmei Granules or SCLM) is a traditional Chinese medicine (TCM) formulation developed by the Teaching Hospital of Chengdu University of Traditional Chinese Medicine. It is formulated based on the classical TCM prescriptions 'San Cai Tang' (Sancai Decoction), 'Jiao Tai Wan', and 'Fructus Mume' (Lianmei Decoction), with modifications. The formulation comprises six main herbal ingredients: Renshen (*Panax ginseng*), Tiandong (*Asparagus cochinchinensis*), Dihuang (*Rehmannia glutinosa*), Wumei (*Prunus mume*), Rougui (*Cinnamomum cassia*), and Huanglian (*Coptis chinensis*). Sancailianmei Particles are primarily developed for the treatment of type 2 diabetes mellitus (particularly the Qi and Yin deficiency syndrome) and its complications, such as diabetic ischemic stroke and diabetic testicular dysfunction. The formulation works by regulating blood glucose levels, improving beta-cell function and insulin resistance, modulating gut microbiota, and exerting anti-inflammatory and antioxidative effects (such as upregulating the Nrf2/HO-1 signaling pathway and inhibiting excessive autophagy).
- Other names
- SCLM ParticleSCLM granulesSancai Lianmei GranuleSancai Lianmei GranulesSancai Lianmei Particles三才连梅颗粒
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)HMOX1 (Heme oxygenase 1)
Beyond the preview
Go deeper on Sancailianmei Particles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sancailianmei Particles.